• Ambu forecasts fiscal 2026/27 organic revenue growth of 9.5-11.5%, with an EBIT margin of 13-15%.
• That compares with fiscal 2025/26 organic growth of 10.1% and an EBIT margin of 13.2%.
• Endoscopy Solutions is expected to deliver around 15% organic growth, remaining the main growth driver.
• Accelerated launch investments replace the roughly 20% EBIT margin objective for 2027/28 with annual earnings growth exceeding organic revenue growth.
• Cash conversion is projected at approximately 30%, down from 39%, reflecting temporarily higher capital spending to support launches and transformation projects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ambu A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.